Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study.
about
Advancing Treatment of Pituitary Adenomas through Targeted Molecular Therapies: The Acromegaly and Cushing Disease ParadigmsPasireotide: a novel treatment for patients with acromegalyHyperglycemia induced by pasireotide in patients with Cushing's disease or acromegalyChallenges in the diagnosis and management of acromegaly: a focus on comorbidities.Targeting kinase signaling pathways with constrained peptide scaffolds.Pegvisomant in acromegaly: an update.Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study.Pasireotide Therapy of Multiple Endocrine Neoplasia Type 1-Associated Neuroendocrine Tumors in Female Mice Deleted for an Men1 Allele Improves Survival and Reduces Tumor Progression.Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly.Safety and tolerability of pasireotide long-acting release in acromegaly-results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) studyExpression of Somatostatin Receptor 2 in Somatotropinoma Correlated with the Short-Term Efficacy of Somatostatin AnaloguesPasireotide in Acromegaly: A Review.Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing's syndrome and acromegaly.Pasireotide for the treatment of acromegaly.Management of Hyperglycemia in Patients With Acromegaly Treated With Pasireotide LAR.Pasireotide in an insulin-requiring diabetic acromegalic patient without worsening of hyperglycemia.Pasireotide for the Medical Management of Feline Hypersomatotropism.Progress in the formulation and delivery of somatostatin analogs for acromegaly.Novel Somatostatin Receptor Ligands Therapies for Acromegaly.How are growth hormone and insulin-like growth factor-1 reported as markers for drug effectiveness in clinical acromegaly research? A comprehensive methodologic review.
P2860
Q26741707-B7503905-3B91-493A-871C-436C2BE9DC01Q26774437-62166D70-1C60-4BAC-ABD1-8884E79AF5B1Q28069603-328C28CF-55C7-4A02-9367-311B25ED5DF6Q30249746-6A3D83D1-BE98-45E0-A2DE-E0600ADDA57CQ30398451-E612643D-5774-475E-A7E7-BE2738EA4888Q33725999-BF25B772-565B-4BDC-A6AF-47BC12E9942BQ35977997-2E03A174-1DD0-49A5-9061-8B90959BEDEBQ36911589-66A1B2EC-89BF-4A0F-BF1E-62340CA4DF4AQ36990184-64575849-C628-40A7-BD26-BD88605BD491Q37578420-86C211BE-574A-4940-B328-8332F5807C52Q37726440-0E1800D4-580B-4C7E-9F7A-3E4C58978688Q38504642-6AD00884-E9DD-407E-90CB-95C52AFBAF9EQ38683309-BB028E01-246C-4B46-943D-B6CF68794E3DQ38710873-33959832-6948-4D74-B72E-D346B8C008FEQ38912799-5774BE36-C107-414E-86DA-E789A5B4F010Q42243689-9E40CBF6-104F-40A2-A017-3A97F5FDF6ADQ42739471-194727C0-E394-4DEA-BB3E-AF746A1A80C9Q47928226-76211D10-E66F-40C0-94E3-7258FA52D356Q52643700-B35899F8-C015-4345-B663-72FB61A2219DQ54939988-101A8AE7-ADDE-4221-887A-B2A2655856EB
P2860
Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Pasireotide LAR maintains inhi ...... multicenter, Phase III study.
@ast
Pasireotide LAR maintains inhi ...... multicenter, Phase III study.
@en
type
label
Pasireotide LAR maintains inhi ...... multicenter, Phase III study.
@ast
Pasireotide LAR maintains inhi ...... multicenter, Phase III study.
@en
prefLabel
Pasireotide LAR maintains inhi ...... multicenter, Phase III study.
@ast
Pasireotide LAR maintains inhi ...... multicenter, Phase III study.
@en
P2093
P2860
P1433
P1476
Pasireotide LAR maintains inhi ...... multicenter, Phase III study.
@en
P2093
Karina Hermosillo Reséndiz
Laura De Marinis
Liudmila Rozhinskaya
Luciana Naves
Marcello D Bronstein
Matthieu Ruffin
Michael Sheppard
Omar Serri
Pamela Freda
YinMiao Chen
P2860
P2888
P304
P356
10.1007/S11102-014-0585-6
P577
2015-06-01T00:00:00Z